Prostate cancer is a significant health concern for men globally, with rising incidence and mortality rates. Early detection ...

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).

A new radiotherapy centre in Milton Keynes was officially opened on Monday saving hundreds of cancer patients a 70-mile round ...

A genetics research laboratory has reached a significant milestone in its efforts to recruit 1,000 volunteers for a prostate ...

Multidisciplinary care, a collaborative approach where various healthcare disciplines come together, is essential for treating those with prostate cancer.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

I am a healthy 89-year-old United States Army veteran. In August 2017, I was diagnosed with advanced prostate cancer and was treated with Lupron and radiation.

European Commission Approves Biocon Biologics’ Denosumab BiosimilarsBengaluru, Karnataka, India, July 3, 2025 Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.